ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-4.37%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$520M
AUM Growth
+$520M
(+7.1%)
Cap. Flow
+$56.8M
Cap. Flow
% of AUM
10.93%
Top 10 Holdings %
Top 10 Hldgs %
45.71%
Holding
253
New
46
Increased
68
Reduced
40
Closed
49
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$14.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$9.17M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
$8.55M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
| 5 |
RAPT Therapeutics
RAPT
|
$5.85M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$11.7M |
| 2 |
Ascendis Pharma
ASND
|
$10.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$9.18M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$6.59M |
| 5 |
Sanofi
SNY
|
$4.8M |
Sector Composition
| 1 | Healthcare | 80.96% |
| 2 | Financials | 3.59% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Utilities | 0.02% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
BioNTech
BNTX
$24.1B
| $455K | 0.08% |
+5,000
| New | +$455K |
|
102
Cidara Therapeutics
CDTX
$1.61B
| $451K | 0.08% |
20,938
-4,000
| -16% | -$86.2K |
|
103
Tenax Therapeutics
TENX
$27.4M
| $450K | 0.08% |
68,741
+34,048
| +98% | +$223K |
|
104
Edgewise Therapeutics
EWTX
$1.53B
| $440K | 0.08% |
+20,000
| New | +$440K |
|
105
Nabors Energy Transition Corp II
NETD
$241M
| $437K | 0.08% |
39,900
| – | – |
|
106
Geron
GERN
$906M
| $423K | 0.08% |
266,176
-71,500
| -21% | -$114K |
|
107
Instil Bio
TIL
$198M
| $422K | 0.08% |
24,328
-7,380
| -23% | -$128K |
|
108
KalVista Pharmaceuticals
KALV
$727M
| $412K | 0.08% |
35,743
-100
| -0.3% | -$1.15K |
|
109
Apellis Pharmaceuticals
APLS
$3.5B
| $372K | 0.07% |
17,000
+2,000
| +13% | +$43.7K |
|
110
argenx
ARGX
$43.6B
| $355K | 0.07% |
+600
| New | +$355K |
|
|
THRD
111
DELISTED
Third Harmonic Bio
THRD
| $347K | 0.06% |
+100,000
| New | +$347K |
|
112
Intuitive Surgical
ISRG
$165B
| $347K | 0.06% |
+700
| New | +$347K |
|
113
BioMarin Pharmaceuticals
BMRN
$11.3B
| $346K | 0.06% |
+4,900
| New | +$346K |
|
114
Dianthus Therapeutics
DNTH
$792M
| $332K | 0.06% |
18,285
+602
| +3% | +$10.9K |
|
115
Neurogene
NGNE
$276M
| $327K | 0.06% |
+27,925
| New | +$327K |
|
116
Establishment Labs
ESTA
$1.12B
| $326K | 0.06% |
+8,000
| New | +$326K |
|
117
Ventyx Biosciences
VTYX
$181M
| $324K | 0.06% |
281,600
+157,070
| +126% | +$181K |
|
|
JVSA
118
DELISTED
JV SPAC Acquisition Corp
JVSA
| $322K | 0.06% |
30,000
| – | – |
|
119
Dyne Therapeutics
DYN
$1.89B
| $315K | 0.06% |
+30,099
| New | +$315K |
|
120
OmniAb
OABI
$223M
| $303K | 0.06% |
126,108
-152,000
| -55% | -$365K |
|
|
JWN
121
DELISTED
Nordstrom
JWN
| $293K | 0.05% |
+12,000
| New | +$293K |
|
122
Kymera Therapeutics
KYMR
$2.99B
| $274K | 0.05% |
10,000
| – | – |
|
123
Phathom Pharmaceuticals
PHAT
$839M
| $268K | 0.05% |
42,800
-12,600
| -23% | -$79K |
|
124
Celldex Therapeutics
CLDX
$1.55B
| $265K | 0.05% |
+14,600
| New | +$265K |
|
125
Iron Horse Acquisitions Corp
IROH
$24.8M
| $262K | 0.05% |
25,000
| – | – |
|